Experts said that the effective results of the Corona virus vaccine produced by the University of Oxford and AstraZeneca, in the elderly, may lead to thinking about giving vaccines to different age groups.
AstraZeneca said in a statement that the vaccine against “Covid-19” is 70% effective in preventing the disease, indicating at the same time that these are temporary results, based on clinical trials conducted on a large scale in both Britain and Brazil, and included 20 thousand people. Among them, 131 people contracted the disease.
In the experiment, the effectiveness of the vaccine increased to 90% in a first group of people who received a half dose, then after a month a full dose, while the effectiveness decreased to 62% in another group that received two doses a month apart, according to Sky News Arabia.
No participant, regardless of the dose, had severe complications from Corona, or was hospitalized.
And decision-makers in this field, such as the US Food and Drug Administration, had previously said that they would approve a vaccine that prevents corona infection, or reduces the severity of the disease in at least 50% of people who have been vaccinated.
The Oxford and AstraZeneca vaccine competes with other vaccines from companies such as Pfizer, Biontec, and Moderna, so unlike its competitors, the Oxford vaccine is cheap to produce and does not need to be stored in very low temperatures.
However, it was found that the group that received the low dose of the Oxford / AstraZeneca vaccine did not include any participants over the age of 55, which means that it is unclear whether the 90% effectiveness applies to the elderly, who are more at risk.
This led to AstraZeneca announcing a new global trial using the low dose regimen, although this is not expected to affect the schedule for regulatory approval and launch of the vaccine in the UK and Europe.
The former director of vaccines at the British Ministry of Health, Professor David Salzbury, told the BBC that additional trials were “important”.
He added: “If this vaccine is obtained that is 90% effective, and it is a cheaper vaccine and requires less stringent cooling procedures than other vaccines, then this will be a wonderful result,” according to the British newspaper “The Guardian”.